Legal Representation
Attorney
Shannon Marie McKeon
USPTO Deadlines
Next Deadline
In Grace Period
Section 8 (6-Year) Declaration Due (Based on registration date 2019-02-12)
Due Date
February 12, 2025
Grace Period Ends
August 12, 2025
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
42 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Jun 20, 2025 | NA75 | E | NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED | Loading... |
Jun 20, 2025 | C75A | O | REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK. | Loading... |
Jun 2, 2025 | APRE | A | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | Loading... |
Feb 12, 2025 | ES75 | I | TEAS SECTION 71 & 15 RECEIVED | Loading... |
Mar 10, 2024 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Feb 12, 2024 | REM3 | E | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | Loading... |
Dec 24, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Oct 28, 2021 | NREP | P | NEW REPRESENTATIVE AT IB RECEIVED | Loading... |
Jun 21, 2019 | FINO | P | FINAL DECISION TRANSACTION PROCESSED BY IB | Loading... |
Jun 4, 2019 | FICS | P | FINAL DISPOSITION NOTICE SENT TO IB | Loading... |
Jun 4, 2019 | FIMP | P | FINAL DISPOSITION PROCESSED | Loading... |
May 12, 2019 | FICR | P | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | Loading... |
Feb 12, 2019 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
Nov 27, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Nov 27, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Nov 24, 2018 | GPNX | P | NOTIFICATION PROCESSED BY IB | Loading... |
Nov 16, 2018 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
Nov 7, 2018 | OPNS | P | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | Loading... |
Nov 7, 2018 | OP2R | P | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | Loading... |
Nov 7, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Oct 17, 2018 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Sep 28, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Sep 27, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Sep 27, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Sep 17, 2018 | GNRT | O | NON-FINAL ACTION E-MAILED | Loading... |
Sep 17, 2018 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Sep 17, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Aug 17, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Aug 17, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Aug 16, 2018 | ALIE | A | ASSIGNED TO LIE | Loading... |
Jul 26, 2018 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jul 24, 2018 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
Jul 24, 2018 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
Feb 16, 2018 | RFNT | P | REFUSAL PROCESSED BY IB | Loading... |
Feb 1, 2018 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | Loading... |
Feb 1, 2018 | RFRR | P | REFUSAL PROCESSED BY MPU | Loading... |
Jan 25, 2018 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | Loading... |
Jan 24, 2018 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jan 23, 2018 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
Jan 19, 2018 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Jan 19, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Jan 18, 2018 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for use in enzyme replacement therapy; pharmaceutical and veterinary preparations, namely, vaccines for the treatment of physical and mental illness; pharmaceutical and veterinary preparations for the treatment of physical and mental illness, namely, pharmaceutical preparations for the prevention and treatment of disorders of the endocrine system, growth hormone deficiencies, hypoparathyroidism, achondroplasia, diabetes, fibroblast growth factor receptor(FGFR)-related skeletal disorders, oncological disorders, ophthalmologic disorders, infectious diseases, enzyme replacement therapy, anti-inflammatory diseases, pain, respiratory system disorders, autoimmune disorders, vaccines, non-alcoholic steatohepatitis, brain diseases, bone diseases, CNS diseases, myopathies, obesity, wounds healing, the hormonal system disorders, namely, growth hormone deficiencies, diabetes and angiogenesis, the ophthalmological system disorders, namely, angiogenesis, the angiogenic system disorders, the central nervous system disorders, namely, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, the immune system disorders, namely, immunologic diseases, namely, autoimmune diseases and immunologic deficiency syndromes, the cardio-vascular system diseases, the metabolic system disorders, namely, diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, the respiratory system, the musculo-skeletal system disorders, namely, growth hormone deficiencies, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries, the genitourinary system disorders, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of inflammatory disorders, namely, anti-inflammatories; pharmaceutical preparations for use in dermatology, namely, dermatitis, eczema, psoriasis; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in tissue and organ transplantation; pharmaceutical preparations for use in in ophthalmology; pharmaceutical preparations for use in the treatment of gastroenterological disorders; sanitary preparations for medical purposes, namely, sanitizing wipes, disinfectants for medical instruments, adhesive tapes for medical purposes, dietetic foods, namely, dietetic sugar substitutes adapted for medical use, all-purpose disinfectants for sanitary purposes; fungicides, herbicides
Class 042
Scientific research within the medical, pharmaceutical and bacteriological area and providing scientific consultancy and information in relation to the aforementioned scientific research, conducting of tests regarding medical applications, namely, conducting clinical trials for others, packaging design, designing and development of medical equipment, designing pharmaceutical and medical preparations, preparation of pharmaceutical formulations, namely, pharmaceutical products development, design and development of granulation technology and tablet technology and providing scientific consultancy and information relating to the design and development of granulation technology and tablet technology
Class 045
Licensing of industrial property; legal services
Additional Information
Design Mark
The mark consists of a polygon that is divided by a white curved band with the top section being in turquoise and the bottom section in blue.
Color Claim
The color(s) turquoise, grey, white and blue is/are claimed as a feature of the mark.
Classification
International Classes
005
042
045